To date, neither Bayshore nor Beximco have received any reports of adverse events related to use of the product. The Directorate General of Drug Administration in Bangladesh said it took samples from 19 companies that produce the drug in the country. When the FDA alert on metformin was made in June 2020, Beximco started testing all new lots produced for NDMA levels before release, he said. Beximco started identifying the root cause of NDMA contamination in metformin formulation when the issue emerged, according to Reza. Beximco does not manufacture metformin API or active pharmaceutical ingredient and source this from a different manufacturer, according to him.

Source: bd News24 September 12, 2020 15:56 UTC